Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P ¼ 0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.
Introduction
Disruption of the natural anatomic and physiologic barriers between the prostatic milieu and the bloodstream is an important factor determining increased serum prostate-specific antigen (PSA) levels. Inflammation alters prostatic duct integrity causing PSA leakage from the acini and ductal lumina. In 1989, Dalton was the first to report total PSA elevation in acute prostatitis. 1 Many experimental and clinical studies suggest a correlation between acute and chronic prostatitis and increased serum PSA levels. [2] [3] [4] [5] [6] Subclinical inflammation of the prostate could elevate serum PSA in asymptomatic patients without clinically detectable prostate cancer. Gerstenbluth et al., 7 in 2002, reported chronic prostatitis as a common finding in radical prostatectomy specimens. In the majority of cases, prostatitis is an incidental pathological finding that causes no clinical symptoms. These patients are categorized by the National Institutes of Health (NIH) into category IV prostatitis (asymptomatic inflammatory prostatitis) (Supplementary Information). It has been suggested that repeating the measurement of PSA in symptomatic men can help avoid unnecessary prostatic biopsy. 8, 9 Although prostatitis may cause PSA elevation, asymptomatic patients are not routinely screened for this disease before transrectal biopsy. The aim of our study was to investigate the possibility of reducing the number of prostate biopsies in patients showing PSA decrease or normalization after antibiotic therapy. This approach could be useful in patients for whom it is necessary to postpone biopsy and in patients, with previous negative biopsies, willing to avoid biopsy until further PSA increase. A secondary aim was to identify the level of PSA reduction that must be reached to avoid biopsy, limiting as much as possible the risk of missing a cancer.
Patients and methods
Ninety-nine asymptomatic Caucasian men requiring urological consultation for PSA between 4 and 10 ng/ dl, with negative rectal examination for cancer and candidate to biopsy, were entered in our study. Exclusion criteria were abnormal mid-void urine, urinary tract infection, urinary symptoms, clinical signs or documented history of prostatitis. The patients should have at least two previous elevated PSA detections, showing no decrease greater than 10%, to confirm the possibility of spontaneous PSA reduction. All patients were submitted to physical examination and rectal exam before biopsy. Prostate gland enlargement was a common finding, but there was no single objective finding indicative of prostate cancer or prostatitis. Since our patients were asymptomatic, they did not undergo prostate massage and laboratory-specific analyses to rule out prostatitis. Written informed consent was obtained from all patients. Basal total-PSA (t-PSA) and free-PSA (f-PSA) determinations were repeated in all patients at study entry. Eighteen patients (18.2%), with repeated PSA values between 10.2 and 20 ng/dl, were accepted in the study as they needed to temporarily postpone the biopsy. These patients were informed of the increased risk of prostate tumour. Ciprofloxacin (500 mg b.i.d.) was given orally for 3 weeks. t-PSA and f-PSA determinations were repeated 2 weeks after therapy. Independently from the value of the repeated PSA, 2-4 weeks after therapy cessation, all patients were submitted to transrectal ultrasoundguided biopsy (biplanar mode, B&K sonograph). Prostate volume was estimated assuming an ellipsoid shape. It was evaluated only at the time of the transrectal biopsy, and no attempt to study volume variations, presumably of small entity, caused by antibiotic therapy was done. Ultrasound-guided transrectal biopsy, using an 18-G needle fitted to an automatic biopsy gun, was performed. The number of cores varied from 12 to 21 according to patients' age, prostate volume, number of previous biopsies and presence of suspicious area detected by ultrasound. In particular, 12 prostate cores were obtained in 61 patients, 14-16 cores in 25 patients owing to suspicious area at ultrasound and 21 cores in 13 patients with previous negative biopsy or with prostate volume between 60 and 82 cm 3 . Local anaesthesia with transrectal infiltration of 5 ml of 20% mepivacaine solution, through a 20-G needle at the junction between each seminal vesicle and the prostate, was performed. Routine haematoxylin-eosin-stained slides were obtained and were routinely examined to avoid any deviation from the usual clinical practice. In addition, a pathological systematic analysis of the specimens was performed to score the inflammation that was graded using a four-point scale according to the system formulated by Irani: 6 grade 0, no inflammatory cells; grade 1, scattered inflammatory cell infiltrate within the stroma without lymphoid nodules; grade 2, non-confluent lymphoid nodules; and grade 3, confluent infiltrate of mononuclear inflammatory cells.
Patients with PSA reduction and negative biopsy will be followed with PSA determinations and digital rectal exam (DRE) at 6-month intervals for the first year and then yearly.
Statistics
Statistical analysis was performed by regression analysis. The univariate associations between tumour absence at biopsy with patients' age, basal t-PSA and f-PSA, t-PSA and f-PSA reduction after therapy were examined and differences assessed by w 2 and Fisher's exact tests. Statistical comparisons of the groups were performed using the Mann-Whitney U test and the Kruskal-Wallis non-parametric analyses of variance. Multivariate logistic regression analysis was performed and significant ORs with 95% confidence interval (CI) were calculated.
Results
The characteristics of the 99 patients entered in our study are reported in Table 1 . Median prostate volume was 37 cm 3 and median t-PSA value 7.3 ng/ml. Ciprofloxacin was well tolerated and treatment interruption for toxicity was never required.
The effect of the antibiotic therapy on t-PSA and f-PSA/t-PSA ratio is shown in Table 2 .
Fifty-nine patients (59.6%) showed t-PSA reduction after therapy. In eight of them (8.1%), PSA decreased below 4 ng/ml. The mean and median PSA reduction rates were 28 and 22%, respectively. The reduction of t-PSA had a widespread variation ranging between 2.4 and 91.4%. The median absolute reduction was 2.0 ng/ml, up to 13.8 ng/ml. PSA ratio remained almost unchanged, with a median value of 0.16 and a median rate of change of 6%, as f-PSA varied according to t-PSA. At statistical analysis, comparing the baseline characteristics of patients with and without t-PSA reduction after antibiotics, the former had a significantly higher baseline PSA value (median value 9.0 vs 5.0 ng/ml; Po0.0001). On the other hand, no difference emerged in terms of age, prostate volume, f-PSA/t-PSA ratio, numbers of cores and previous negative biopsies. Routine histology revealed benign prostate hyperplasia, prostate carcinoma and chronic prostatitis in 65 (65.7%), 28 (28.3%) and 6 (6%) patients, respectively (Table 3) . Conversely, the systematic grading of the inflammation showed grade 0 in 35 patients and small microscopic foci of prostatitis in 60 patients, grade 1, 2 and 3 in 52, 6 and 5 patients, respectively. No correlation was found between basal PSA values and routine histology (P ¼ 0.49) or inflammation score. Median PSA basal value in patients with grade 0-1 and 2-3 was 6.8 (range: 4.1-17.0) and 8.7 ng/ml (range: 5.0-15.2), respectively (P ¼ 0.44). Similarly, no difference emerged between the PSA reduction rate after antibiotics and the grade of inflammation. Median PSA reduction was 10.2 and 14.9% in patients Excluding the 18 patients with initial PSA values above 10 ng/ml, out of the remaining 81 patients, no cancer was detected in six patients with PSA reduction to less than 50% of the basal value and in three more patients with PSA decreased below 4 ng/ml (Table 4) . Considering age, number of biopsy cores, prostate volume, baseline PSA, f-PSA/t-PSA ratio, absolute PSA variation and PSA reduction rate, only prostate volume and PSA reduction rate showed a correlation with the absence of prostate cancer. However, prostate volume had no statistical significance at multivariate analysis, as it was equally distributed between patients with or without PSA reduction. On the other hand, PSA reduction rate showed an independent strong correlation with the absence of prostate cancer at biopsy, ORs varying from 1.2 to 3.9 (median 2.6). Particularly, for PSA reduction rates over 50 and 70%, PSA sensitivity was 75 and 100% and negative predictive value 77 and 100%, respectively.
Discussion
The present study analyses the effect of antibiotic therapy on f-PSA and t-PSA to investigate if a relevant PSA reduction induced by antibiotics could be related to a decreased cancer detection rate at biopsy. In particular, we investigated whether antibiotics lower PSA to normal levels, thus permitting postponement of prostate biopsy until further PSA increase. It has recently been suggested that, in managing men with elevated PSA, the decision for biopsy based on one single value may be inappropriate. Prostate biopsy could, in fact, be avoided or postponed in men with normal DRE who have a normal repeated PSA, eventually after a course of antibiotics. 8, 9 Minimizing negative prostate biopsies is an important goal. Nadler et al. 10 demonstrated the presence of chronic inflammatory cells in 64.3% of men undergoing transrectal ultrasound biopsy for elevated PSA. Brett et al. 11 found, in 300 randomly selected men, category IV prostatitis prevalence of 32.2% and serum PSA levels significantly higher (P ¼ 0.0004) than in men without prostatitis.
In our study, the routine histological exam revealed chronic prostatitis in a small number of specimens. The lack of correlation was probably due to the fact that our patients were asymptomatic and that histology was obtained after antibiotics. On the other hand, when an extensive pathological examination was performed to score the inflammation, thus also detecting very small foci of chronic prostatitis, 60% of patients showed foci of inflammation, even after antibiotics. In accordance with the findings of Kwak et al., 12 we did not find any statistically significant correlation between the PSA values and the extent of inflammation in biopsy specimens. Apparently, this observation does not support the correlation between antibiotics and PSA reduction. Nevertheless, patients with PSA reduction after antibiotics had a baseline t-PSA significantly higher than that of the other patients in spite of the lower incidence of carcinoma. Although the exact implication of this finding is not completely clear, the higher PSA values could be due to the fact that small foci of inflammation could alter prostate integrity more extensively than small foci of carcinoma.
In our experience, PSA decreased after antibiotics in almost 60% of patients, returning within normal limits in 8% of them. Thus, PSA normalization was far less common than that reported by other authors in patients with increased PSA and laboratory signs of PSA reduction after antibiotics V Serretta et al prostatitis. 4, 5, 13 After antibiotic treatment, Potts et al. documented PSA normalization in 42% of 51 patients and Brett et al. 11 in 41% of 86 patients with an increased PSA and diagnosis of prostatitis.
A major bias of our study is that it is not a randomized one. In some patients, serum PSA would have dropped without antibiotics owing to the spontaneous variation in serum PSA. Thus, our results could be due to a lower incidence of prostate cancer in patients with greater PSA variability. We tried to minimize the risk of PSA variability, including only patients with persistent elevated PSA values in at least two determinations before study entry. On the other hand, it must be emphasized that our results can be also applied to patients showing similar spontaneous PSA reduction.
Another limitation is that we could not establish the proportion of men, albeit small, who could have a clinically detectable chronic prostatitis. Our patients were not screened for prostatitis as they were asymptomatic.
Our results are very similar to those obtained by Hochreiter et al. 8 in 35 patients with NIH category IV prostatitis and elevated PSA. They showed, after antibacterial therapy, PSA reduction in 63% of patients, with PSA returning to normal values in 9% of them, thus avoiding prostate biopsy.
In our experience, the f-PSA/t-PSA ratio was not a discriminator between cancer and chronic inflammation, even after a course of antibacterial therapy, as f-PSA appeared to vary according to t-PSA. Many other studies investigated the correlation between PSA, f-PSA/t-PSA ratio and inflammatory disorders of the prostate [14] [15] [16] with contradictory results. Scattoni et al., 16 compared the pathology results of prostatectomy with the preoperative f-PSA/t-PSA ratio and found a decreased ratio in the presence of histological signs of acute prostatitis. Lorente et al. 17 found significant variations in t-PSA and f-PSA/ t-PSA ratios in patients with benign prostatic hyperplasia (BPH)-associated prostatitis and not in patients with BPH or cancer. On the contrary, Ornstein et al. 18 did not find any change in f-PSA/t-PSA ratio in prostatitis. Yavascaoglu et al., 19 in accordance with our results, demonstrated t-and f-PSA reduction but no variation in f-PSA/t-PSA ratio after antibacterial therapy in patients with PSA levels between 4 and 10 ng/ml.
Our study shows a significantly lower cancer detection rate in patients with decreased PSA after antibiotic therapy, demonstrating a correlation between PSA reduction and negative biopsy, OR varying from 1.2 to 3.9 for reduction percentages between 10 and 90%. Out of 99 patients, considering PSA reduction greater than 70% and/or below 4 ng/ml, 9% of prostate biopsies could be avoided or postponed until further PSA increase, missing no prostate tumour. Excluding patients with PSA value greater than 10 ng/ml, a PSA reduction rate of 50% can be adopted and 11% of biopsies avoided until further PSA increase. It must be, however, emphasized that a long follow-up is needed to determine if any of these men will have prostate cancer in the near future, and larger studies are needed to identify the optimal PSA reduction level to postpone biopsy.
Obviously, a 3-week course of antibiotic treatment is an inappropriate and certainly not a cost-effective approach to reduce the number of prostate biopsies in unselected cases. However, this approach can be adopted in selected patients needing to postpone biopsy and in those patients with previous negative biopsies reluctant to undergo a second or a third procedure. In patients showing PSA decreasing to less than 50% of initial value or normalizing after antibiotics, PSA could be monitored postponing biopsy until further increase. On the other hand, our results are also valid for patients showing spontaneous PSA variations.
Conclusions
After antibiotic treatment, the resultant PSA reduction rate was strongly related to the absence of cancer at biopsy. PSA decreases in 60% and returns within normal limits in 8% of patients. Eleven per cent of patients with PSA between 4 and 10 ng/ml will show, after antibiotics, a decrease of PSA value to less than 50% of the initial value and/or below 4 ng/ml. The risk of missing a cancer in these patients is low and PSA can be monitored until further rise. Obviously, antibiotics cannot be administered in all patients to avoid biopsy in a small number of them, but could be given in selected cases requiring postponement of prostate biopsy and in patients with previous negative biopsies reluctant to repeat the procedure.
